<code id='392CC0809D'></code><style id='392CC0809D'></style>
    • <acronym id='392CC0809D'></acronym>
      <center id='392CC0809D'><center id='392CC0809D'><tfoot id='392CC0809D'></tfoot></center><abbr id='392CC0809D'><dir id='392CC0809D'><tfoot id='392CC0809D'></tfoot><noframes id='392CC0809D'>

    • <optgroup id='392CC0809D'><strike id='392CC0809D'><sup id='392CC0809D'></sup></strike><code id='392CC0809D'></code></optgroup>
        1. <b id='392CC0809D'><label id='392CC0809D'><select id='392CC0809D'><dt id='392CC0809D'><span id='392CC0809D'></span></dt></select></label></b><u id='392CC0809D'></u>
          <i id='392CC0809D'><strike id='392CC0809D'><tt id='392CC0809D'><pre id='392CC0809D'></pre></tt></strike></i>

          leisure time

          leisure time

          author:leisure time    Page View:878
          JUUL store sign -- health coverage from STAT
          Stephanie Keith/Getty Images

          Documents released this week shed new light on an aggressive strategy from vape maker Juul to court Black leaders, including the Rev. Al Sharpton, to publicly support its e-cigarettes.

          Beginning in 2018, Juul executives, including the company’s CEO, discussed six- and seven-figure partnerships with civil rights organizations, one of which would have seen it send as much as $7 million to Sharpton’s group, according to internal emails and documents that were released this week as part of a legal settlement with the state of North Carolina.

          advertisement

          It’s not clear how much the company ultimately spent on the partnerships.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          First U.S. drug developed to treat liver disease MASH is approved
          First U.S. drug developed to treat liver disease MASH is approved

          AdobeTheFoodandDrugAdministrationonThursdayapprovedthefirstmedicinedevelopedspecificallytotreatthese

          read more
          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more

          WHO recommends second malaria vaccine

          JeromeDelay/APJusttwoyearsaftertheWorldHealthOrganization’shistoricrecommendationofthefirstmalariava